COVID-19
Conditions
Keywords
calcitriol, HsCRP
Brief summary
This research is a study that compares the administration of calcitriol with the outcomes of COVID-19 patients
Detailed description
This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into two groups. The control group received standard therapy, while the treatment group received calcitriol 2x400 iu per day.
Interventions
DRUGCalcitriol
The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma
OTHERPlacebo
Placebo give 2x1 per day for five day
Sponsors
Universitas Sebelas Maret
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
This study used calcitriol and a placebo, which were similar in shape; researchers and patients did not know who was getting the drug or placebo.
Intervention model description
This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into two groups. The control group received standard therapy, while the treatment group received calcitriol 2x400 iu per day.
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* COVID-19 patients, hospitalized patients, and patients aged 18-60 years
Exclusion criteria
* pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HsCRP | Hs CRP (high sensitive c reactive protein) examination was carried out on the first day of hospitalization and the 5th day of hospitalization | High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation |
Countries
Indonesia
Outcome results
None listed